Please login to the form below
tumour agnostic therapies
This page shows the latest tumour agnostic therapies news and features for those working in and with pharma, biotech and healthcare.
Fool’s gold or pot of gold? The challenges of demonstrating the value of tumour agnostic therapies
By George Forsyth. Targeted therapies are considered the future of medicine and tumour agnostic (TA) therapies are no exception. ... Manufacturers look set to try to capitalise on this with a further ten tumour-agnostic therapies anticipated to launch in
Latest news
-
NICE leaves the ‘the NHS door’ open despite rejecting Bayer’s Vitrakvi
Last June, NHS England chief executive Simon Stevens (pictured left) announced that the health service wants to fast-track tumour-agnostic drugs, like Vitrakvi and Rozlytrek. ... Stevens said that NHS England would attempt to work with industry to
-
England to fast-track tumour agnostic drugs like Vitrakvi – if the price is right
NHS England will now work with the industry to prepare for the fast-tracking of these tumour agnostic therapies and:. ... Bring together different cancer specialists to ensure all patients who could benefit from tumour agnostic drugs are identified.
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
Between November 2016 and October 2017, the FDA approved 31 new therapies for more than 16 types of tumour, including the first cell-based therapies, the first tumour-agnostic drugs and ... molecular defects that are driving its growth, in contrast to
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Bristol Myers Squibb announces positive trial results for treatment of MS
- My journey advancing the science in pulmonary hypertension
- A new era for UK-Japanese scientific research relations
- Enanta takes legal action against Pfizer over Paxlovid patent infringement
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- Pfizer and BioNTech share positive results for Omicron-adapted COVID-19 vaccine
- NICE issues final draft recommending Novartis’ Scemblix to treat chronic myeloid leukaemia
- Alzheimer's Research UK supports government plans for clinical research
- GSK announces The HealthTree Foundation’s multiple myeloma programme as first ‘Think Tank’ challenge winner
- NRG Therapeutics partners with Domainex to develop neurodegenerative disease treatment
- Innovative Trials opens first US office
- Scanning for Health Indicators and Risks Through Your Smartphone
- Realising the potential of omnichannel in medical communications
- College of Medicine launches Beyond Pills campaign to tackle overprescribing in UK health system
- AI is transforming pharma R&D – now it can transform pharma marketing
- J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma
- Six UK universities receive grant for research into motor neurone disease
- My journey advancing the science in pulmonary hypertension
PMHub
CSafe Global
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...
Latest intelligence
- Our Top 5 Pharma Picks From Cannes Lions
- Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
